Q-omics provides the consensus-scored GAGE1 profile across patient tissues and cancer cell-line models. GAGE1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GAGE1 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, GAGE1 RNA expression shows 3,833 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight LIHC, LUAD, and UCEC as cancer lineages where GAGE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAGE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAGE1 survival associations across molecular data types. GAGE1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAGE1 RNA expression–survival associations across cancer types. High GAGE1 expression shows unfavorable associations in LIHC, MESO, COAD, OV, DLBC and UVM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GAGE1 RNA expression.
This table summarizes GAGE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GAGE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAGE1 shows higher tumor expression in LUAD. The LUAD box plot shows higher GAGE1 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p = .029).
This table shows molecular features associated with GAGE1 in patient tissues and cancer cell lines. In patient samples, GAGE1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, GAGE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma.
